Tesofensine
Also known as: NN7952
Triple monoamine reuptake inhibitor that significantly suppresses appetite and increases energy expenditure. Originally developed for neurological conditions, repurposed for obesity treatment.
Research Status
Moderate Clinical Data
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Often transient and resolves within 1-2 weeks. Take with food if tolerated. Dose titration reduces incidence.
Due to increased dopamine and norepinephrine. Take dose in early morning (6-8 AM). Avoid evening dosing. May improve with continued use.
Dose-dependent effect. Monitor heart rate regularly. Baseline and periodic cardiovascular assessment recommended. Discontinue if sustained elevation or palpitations occur.
Noradrenergic effect. Monitor blood pressure at baseline and regularly during treatment. Contraindicated in uncontrolled hypertension.
Usually mild and transient. May respond to over-the-counter analgesics.
Increase water intake. Use sugar-free lozenges if needed.
Dose-dependent. May occur during titration phase. Consider slower dose escalation.
Fine tremor may occur, particularly at higher doses. Usually resolves with dose reduction or continued use.
Increased thermogenesis and sympathetic activation. Usually mild and transient.
Increased fiber intake and hydration recommended. Stool softeners may help if needed.
Risk if combined with other serotonergic agents (SSRIs, SNRIs, MAOIs, tramadol). Symptoms include agitation, confusion, rapid heart rate, high blood pressure, dilated pupils, muscle rigidity. Requires immediate medical attention. Contraindicated with serotonergic medications.
Mood changes, suicidal ideation, or behavioral changes reported in some users. Monitor mental health closely. Discontinue and seek medical evaluation if psychiatric symptoms emerge.
Cardiac arrhythmias possible, particularly in susceptible individuals or at higher doses. Baseline ECG recommended. Discontinue immediately if arrhythmia suspected.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 0.25-1 mg |
| Frequency | 1x daily |
| Timing | Morning |
| Route | Oral |
Oral administration. Start at 0.25 mg daily. Titrate upward by 0.25 mg increments every 4 weeks based on tolerability and response. Maximum studied dose is 1 mg daily. Research compound — not approved for clinical use.
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline — use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2–8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
| Half-life | Approximately 20-24 hours (oral) |
Tesofensine is a triple monoamine reuptake inhibitor that blocks the reuptake of serotonin, norepinephrine, and dopamine in the central nervous system. By increasing synaptic concentrations of these neurotransmitters, it suppresses appetite through hypothalamic pathways and increases energy expenditure, promoting weight loss. It was originally developed for neurological conditions but has been repurposed for obesity treatment due to its potent metabolic effects.
Serotonergic pathway
Increased serotonin signaling in the hypothalamus promotes satiety and reduces food intake via 5-HT2C receptor activation on pro-opiomelanocortin (POMC) neurons.
Noradrenergic pathway
Enhanced norepinephrine levels increase sympathetic nervous system activity, elevating metabolic rate and thermogenesis.
Dopaminergic pathway
Increased dopamine signaling enhances motivation, reduces reward-driven eating, and supports sustained energy and alertness.
- Triple monoamine reuptake inhibitor — blocks reuptake of serotonin, norepinephrine, and dopamine simultaneously
- Suppresses appetite through hypothalamic satiety centers
- Increases resting energy expenditure and thermogenesis
- Crosses the blood-brain barrier due to lipophilic structure
- Oral bioavailability allows once-daily dosing
- Originally developed for Parkinson's disease and depression before obesity indication
Track your Tesofensine research
Free account. No credit card required.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Tesofensine is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.